NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease.
Varanese
Sara
S
Howard
Jonathan
J
Di Rocco
Alessandro
A
D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015259:Dopamine Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy*; D005260:Female; D006801:Humans; D015994:Incidence; D007980:Levodopa / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008559:Memantine / Q000494:pharmacology* / Q000627:therapeutic use*; D016202:N-Methylaspartate / Q000037:antagonists & inhibitors*; D010300:Parkinson Disease / Q000188:drug therapy*
D000978:Antiparkinson Agents; D015259:Dopamine Agents; D007980:Levodopa; D016202:N-Methylaspartate; D008559:Memantine